Clinical trial
Randomized, Double-blind, Active-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of GC3111 in Healthy Adults
NCT04238975 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-blind, Active-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of GC3111 in Healthy Adults
- Lead sponsor
- Green Cross Corporation
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 14, 2019
- Completion date
- May 31, 2021
- Enrollment
- 213 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.